Effects of tocilizumab and dexamethasone on the downregulation of proinflammatory cytokines and upregulation of antioxidants in the lungs in oleic acid-induced ARDS

dc.contributor.author Terzi, Funda
dc.contributor.author Demirci, Beste
dc.contributor.author Çınar, İrfan
dc.contributor.author Alhilal, Mohammad
dc.contributor.author Erol, Huseyin Serkan
dc.date.accessioned 2022-12-21T08:05:59Z
dc.date.available 2022-12-21T08:05:59Z
dc.date.issued 2022
dc.description.abstract Abstract Background: Acute respiratory distress syndrome (ARDS) is a life-threatening disease caused by the induction of infammatory cytokines and chemokines in the lungs. There is a dearth of drug applications that can be used to prevent cytokine storms in ARDS treatment. This study was designed to investigate the efects of tocilizumab and dexamethasone on oxidative stress, antioxidant parameters, and cytokine storms in acute lung injury caused by oleic acid in rats. Methods: Adult male rats were divided into fve groups: the CN (healthy rats, n=6), OA (oleic acid administration, n=6), OA+TCZ-2 (oleic acid and tocilizumab at 2 mg/kg, n=6), OA+TCZ-4 (oleic acid and tocilizumab at 4 mg/kg, n=6), and OA+DEX-10 (oleic acid and dexamethasone at 10 mg/kg, n=6) groups. All animals were euthanized after treatment for histopathological, immunohistochemical, biochemical, PCR, and SEM analyses. Results: Expressions of TNF-α, IL-1β, IL-6, and IL-8 cytokines in rats with acute lung injury induced by oleic acid were downregulated in the TCZ and DEX groups compared to the OA group (P<0.05). The MDA level in lung tissues was statistically lower in the OA+TCZ-4 group compared to the OA group. It was further determined that SOD, GSH, and CAT levels were decreased in the OA group and increased in the TCZ and DEX groups (P<0.05). Histopathological fndings such as thickening of the alveoli, hyperemia, and peribronchial cell infltration were found to be similar when lung tissues of the TCZ and DEX groups were compared to the control group. With SEM imaging of the lung tissues, it was found that the alveolar lining layer had become indistinct in the OA, OA+TCZ-2, and OA+TCZ-4 groups. Conclusions: In this model of acute lung injury caused by oleic acid, tocilizumab and dexamethasone were efective in preventing cytokine storms by downregulating the expression of proinfammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8. Against the downregulation of antioxidant parameters such as SOD and GSH in the lung tissues caused by oleic acid, tocilizumab and dexamethasone upregulated them and showed protective efects against cell damage. en_US
dc.identifier.citation Terzi, F., Demirci, B., Çınar, İ., Alhilal, M., & Erol, H. S. (2022). Effects of tocilizumab and dexamethasone on the downregulation of proinflammatory cytokines and upregulation of antioxidants in the lungs in oleic acid-induced ARDS. Respiratory Research, 23(1), 1-11. en_US
dc.identifier.doi 10.1186/s12931-022-02172-w
dc.identifier.issn 1465-993X
dc.identifier.scopus 2-s2.0-85138206381
dc.identifier.uri https://doi.org/10.1186/s12931-022-02172-w
dc.identifier.uri https://pubmed.ncbi.nlm.nih.gov/36115998/
dc.identifier.uri https://www.scopus.com/record/display.uri?eid=2-s2.0-85138206381&origin=resultslist&sort=plf-f&src=s&st1=10.1186%2fs12931-022-02172-w&sid=9397adc674edcd1429d7a3bb6d915b60&sot=b&sdt=b&sl=31&s=DOI%2810.1186%2fs12931-022-02172-w%29&relpos=0&citeCnt=1&searchTerm=
dc.identifier.uri https://hdl.handle.net/20.500.12514/3180
dc.identifier.uri https://www.webofscience.com/wos/woscc/full-record/WOS:000854850600001?AlertId=d383397b-4355-449e-9419-70f9e0e77c15&SID=EUW1ED0E39ELwQcf8Mw3SbSiv2Y5U
dc.language.iso en en_US
dc.publisher BMC en_US
dc.relation.ispartof Respiratory Research en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject ARDS, Tocilizumab, Dexamethasone, Oleic acid, Rat en_US
dc.title Effects of tocilizumab and dexamethasone on the downregulation of proinflammatory cytokines and upregulation of antioxidants in the lungs in oleic acid-induced ARDS en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.bip.impulseclass C4
gdc.bip.influenceclass C5
gdc.bip.popularityclass C4
gdc.coar.access open access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department Sağlık Bilimleri Fakültesi en_US
gdc.description.endpage 11 en_US
gdc.description.issue 1 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q1
gdc.description.startpage 1 en_US
gdc.description.volume 23 en_US
gdc.description.wosquality Q1
gdc.identifier.openalex W4296139710
gdc.identifier.pmid 36115998
gdc.identifier.wos WOS:000854850600001
gdc.index.type WoS en_US
gdc.index.type Scopus en_US
gdc.index.type PubMed en_US
gdc.oaire.accesstype GOLD
gdc.oaire.diamondjournal false
gdc.oaire.impulse 21.0
gdc.oaire.influence 2.986394E-9
gdc.oaire.isgreen true
gdc.oaire.keywords Male
gdc.oaire.keywords Acute Lung Injury
gdc.oaire.keywords Down-Regulation
gdc.oaire.keywords Antibodies, Monoclonal, Humanized
gdc.oaire.keywords Antioxidants
gdc.oaire.keywords Dexamethasone
gdc.oaire.keywords Diseases of the respiratory system
gdc.oaire.keywords Animals
gdc.oaire.keywords Lung
gdc.oaire.keywords Respiratory Distress Syndrome
gdc.oaire.keywords RC705-779
gdc.oaire.keywords Interleukin-6
gdc.oaire.keywords Superoxide Dismutase
gdc.oaire.keywords Tumor Necrosis Factor-alpha
gdc.oaire.keywords Research
gdc.oaire.keywords Interleukin-8
gdc.oaire.keywords ARDS, Tocilizumab, Dexamethasone, Oleic acid, Rat
gdc.oaire.keywords Tocilizumab
gdc.oaire.keywords Oleic acid
gdc.oaire.keywords Rats
gdc.oaire.keywords Up-Regulation
gdc.oaire.keywords Rat
gdc.oaire.keywords Cytokines
gdc.oaire.keywords ARDS
gdc.oaire.keywords Cytokine Release Syndrome
gdc.oaire.keywords Oleic Acid
gdc.oaire.popularity 1.7631358E-8
gdc.oaire.publicfunded false
gdc.oaire.sciencefields 0301 basic medicine
gdc.oaire.sciencefields 03 medical and health sciences
gdc.oaire.sciencefields 0303 health sciences
gdc.openalex.collaboration National
gdc.openalex.fwci 6.96654874
gdc.openalex.normalizedpercentile 0.97
gdc.openalex.toppercent TOP 10%
gdc.opencitations.count 14
gdc.plumx.mendeley 17
gdc.plumx.pubmedcites 9
gdc.plumx.scopuscites 22
gdc.scopus.citedcount 22
gdc.virtual.author Alhılal, Mohammad
gdc.wos.citedcount 23
relation.isAuthorOfPublication 467d0c32-7caf-48ef-ba50-8ecf629453d2
relation.isAuthorOfPublication.latestForDiscovery 467d0c32-7caf-48ef-ba50-8ecf629453d2
relation.isOrgUnitOfPublication 1afe7739-9ea9-4c3b-af5c-fb0baee4f95c
relation.isOrgUnitOfPublication 632fabc5-6bb5-43ef-8a92-8f603b8b9d34
relation.isOrgUnitOfPublication 39ccb12e-5b2b-4b51-b989-14849cf90cae
relation.isOrgUnitOfPublication.latestForDiscovery 1afe7739-9ea9-4c3b-af5c-fb0baee4f95c

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
s12931-022-02172-w.pdf
Size:
2.47 MB
Format:
Adobe Portable Document Format
Description:
Full Text - Article

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description: